107 results on '"Gaillez C"'
Search Results
2. AB1443 CONSISTENT SAFETY PROFILE OF SECUKINUMAB IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: UPDATE ON THE DATA FROM POOLED CLINICAL TRIALS
3. POS0225 HOW WELL DOES ULTRASOUND-ASSESSED SYNOVITIS IN REDUCED JOINT SETS PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS? - EXPLORATORY RESULTS FROM A PHASE 3B STUDY
4. Impact de l’hyperuricémie sur les caractéristiques cliniques et radiographiques et la réponse au sécukinumab dans le rhumatisme psoriasique : analyse post hoc des données poolées de 5 études de phase 3
5. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
6. Impact of achievement of the simultaneous combined ACR50 plus PASI 100 response on treat-to-target outcomes: Exploratory analyses from the EXCEED head-to-head study
7. POS1065 IMPACT OF HYPERURICEMIA ON CLINICAL PHENOTYPE, COMORBIDITIES, AND RESPONSE TO SECUKINUMAB IN PSORIATIC ARTHRITIS: POST HOC ANALYSIS OF FUTURE AND MAXIMISE STUDIES
8. OP0260 RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO csDMARDs: DATA FROM THE ULTIMATE TRIAL
9. OP0294 REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL
10. POS1022 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5 DURING THE FIRST 24 WEEKS
11. POS1016 RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5
12. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis
13. Réponse échographique et clinique de l’atteinte des synovites chez les patients atteints de rhumatisme psoriasique traités par sécukinumab : résultats de l’étude ULTIMATE
14. Résolution des enthésites chez les patients atteints de rhumatisme psoriasique et traités par sécukinumab ou adalimumab : analyse post-hoc de l’étude EXCEED
15. POS0197 RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL
16. POS0194 ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED
17. POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY
18. POS1050 SECUKINUMAB LEADS TO IMPROVEMENT ACROSS PSORIATIC ARTHRITIS MANIFESTATIONS OVER 2 YEARS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR: A POST HOC ANALYSIS OF FUTURE 5
19. POS1044 EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB ON ACR CORE COMPONENTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE EXCEED STUDY
20. OP0226 TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY
21. L’atomoxétine (Strattera ®), une alternative thérapeutique dans le trouble déficit de l’attention/hyperactivité de l’enfant (TDAH)
22. Activité résiduelle de la maladie chez les patients atteints de rhumatisme psoriasique traités par sécukinumab et adalimumab ayant obtenu une rémission ou une faible activité de la maladie : étude de phase 3b, face-face, randomisée, en double aveugle
23. Effet du sécukinumab sur la réduction des synovites évaluée par échographie Doppler puissance chez des patients atteints de rhumatisme psoriasique actif et naïfs de biothérapie : résultats d’une étude de phase 3 randomisée et contrôlée par placebo
24. THU0373 SECUKINUMAB DOSE ESCALATION ON ACR RESPONSES IN ANTI-TUMOUR NECROSIS FACTOR NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR DATA FROM THE PHASE 3 FUTURE 4 AND FUTURE 5 STUDIES
25. Fibrosis quística del páncreas
26. Secukinumab Sustains Individual Clinical Responses Over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
27. Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS)-Related Remission: 2-Year Results from a Phase 3 Study
28. Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years:long-term data from the future 1 and future 2 studies
29. Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from the Phase 3 Randomised, Multicentre, Double-blind, Placebo-controlled FUTURE 2 study
30. SAT0463 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through 3 years: long-term data from the future 1 and future 2 studies
31. AB0033 The identification of IL-17A+, IL-17RA+ and IL-17RC+ lymphoid and myeloid cells in blood of treatment naÏve early and in synovial fluid of established psoriatic arthritis patients
32. HOW WELL DOES ULTRASOUND-ASSESSED SYNOVITIS IN REDUCED JOINT SETS PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS? - EXPLORATORY RESULTS FROM A PHASE 3B STUDY.
33. No Increase in Incidence of Inflammatory Bowel Disease Among Secukinumab-treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
34. Reduction in fatigue in patients with active psoriatic arthritis is sustained over 2 years:long-term results of two phase 3 studies of secukinumab
35. Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years:Long-Term Results of Two Phase 3 Studies with Secukinumab
36. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results from the APPRAISE study
37. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study
38. THU0442 Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years: Long-Term Results of Two Phase 3 Studies with Secukinumab
39. OP0113 No Increased Incidence of Inflammatory Bowel Disease among Secukinumab-Treated Patients with Moderate To Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
40. FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study: Table 1.
41. Wirksamkeit von Canakinumab bei Biologika-naiven versus Biologika-exponierten sJIA-Patienten
42. Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
43. Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
44. Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
45. Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
46. Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
47. THU0277 Gene Expression in Whole Blood Predicts the Abatacept–Methotrexate Combination Responsiveness in Rheumatoid Arthritis: Preliminary Results from the Power Doppler Ultrasonography Appraise Study
48. OP0185 Efficacy of Canakinumab in Biologic NaÏVe versus Previously Biologic-Exposed SJIA Patients
49. OP0180 Maintenance of Efficacy by Canakinumab Treatment in Systemic Juvenile Idiopathic Arthritis Patients
50. Early response to abatacept plus MTX in MTX-IR RA patients using power doppler ultrasonography: An open-label study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.